This 2025 study tested curcumin monoglucuronide (CMG), a compound the body makes from curcumin. CMG bound and blocked MMP13 and MMP-8, protected cartilage explants from MMP-driven breakdown, and in rats with a cut knee ligament held back cartilage degeneration better than BI-4394, a dedicated MMP13 blocker.
Building on earlier computer modelling that suggested CMG binds the MMPs that destroy cartilage matrix, the researchers used several physical and chemical methods to test whether it binds and blocks MMP13 and MMP-8. They then tested it on cartilage explants in the lab, and in rats after anterior cruciate ligament transection, a surgical model of joint damage, against BI-4394, a specific MMP13 inhibitor. Separate tests looked at cell growth and inflammatory genes.
CMG bound to MMP13 and MMP-8 and blocked their activity. It protected cartilage explants from MMP-driven destruction. In the rats it was more effective than BI-4394 at holding back cartilage degeneration. In the lab, CMG did not affect chondrocyte growth or the expression of NF-kB-driven inflammatory genes. The authors argue that blocking both MMP13 and MMP-8 matters for better results.
The abstract gives no doses, route of delivery or animal numbers. CMG is a specific metabolite, not curcumin itself, and the study does not show how much CMG a person makes after eating curcumin. A surgical ligament injury in rats is a model, not a person's knee.
Most curcumin studies here show it lowering how much MMP13 cells make, through cell signalling. This one reports a curcumin metabolite blocking the enzyme's activity directly, a different step, and it did so without changing NF-kB-driven genes.
In lab and animal studies, yes. Curcumin lowered MMP13 in rat cartilage cells exposed to IL-1 beta, and a curcumin metabolite bound and blocked MMP13 directly and...
Because it acts at the step reviews call irreversible. MMP13 is the main enzyme cutting type II collagen in damaged cartilage, and that collagen renews very slowly. Mice...